Panbela Therapeutics, Inc. (PBLA)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Sep 3, 2026, 4:00 PM EST
Panbela Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Cash & Equivalents | 0.14 | 2.58 | 1.29 | 11.87 | 9.02 | 2.45 |
Short-Term Investments | 4.59 | - | - | - | - | - |
Cash & Short-Term Investments | 4.73 | 2.58 | 1.29 | 11.87 | 9.02 | 2.45 |
Cash Growth | 421.17% | 100.62% | -89.17% | 31.53% | 268.39% | 74.31% |
Other Receivables | 0.33 | 0.18 | 0.05 | 0.32 | 0.32 | 0.36 |
Receivables | 0.33 | 0.18 | 0.05 | 0.32 | 0.32 | 0.36 |
Prepaid Expenses | 0.11 | 0.3 | 0.44 | 0.09 | 0.41 | 0.28 |
Total Current Assets | 5.17 | 3.06 | 1.78 | 12.28 | 9.76 | 3.09 |
Other Long-Term Assets | - | 8.74 | 3.2 | 0.59 | 0.06 | 0.05 |
Total Assets | 5.17 | 11.8 | 4.98 | 12.87 | 9.81 | 3.14 |
Liabilities
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Accounts Payable | 10.95 | 9.94 | 2.87 | 0.64 | 0.55 | 0.6 |
Accrued Expenses | 5.99 | 1.38 | 3.32 | 2.02 | 0.81 | 0.3 |
Short-Term Debt | 2.2 | - | 0.65 | - | - | 0.74 |
Current Portion of Long-Term Debt | 1 | 1 | 1 | - | - | 0.12 |
Total Current Liabilities | 20.14 | 12.32 | 7.83 | 2.66 | 1.37 | 1.76 |
Long-Term Debt | 3.19 | 4.19 | 5.19 | - | - | - |
Total Liabilities | 23.34 | 16.51 | 13.03 | 2.66 | 1.37 | 1.76 |
Shareholders' Equity
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Common Stock | 0.01 | - | - | - | 0.01 | 0.01 |
Additional Paid-In Capital | 128.22 | 120.04 | 82.29 | 66.24 | 54.85 | 42.33 |
Retained Earnings | -146.94 | -125.5 | -91.09 | -56.16 | -46.03 | -41.26 |
Treasury Stock | -0 | -0 | - | - | - | - |
Comprehensive Income & Other | 0.54 | 0.75 | 0.76 | 0.13 | -0.38 | 0.31 |
Shareholders' Equity | -18.17 | -4.71 | -8.05 | 10.21 | 8.45 | 1.39 |
Total Liabilities & Equity | 5.17 | 11.8 | 4.98 | 12.87 | 9.81 | 3.14 |
Additional Metrics
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Total Debt | 6.39 | 5.19 | 6.84 | - | - | 0.86 |
Net Cash (Debt) | -1.67 | -2.62 | -5.56 | 11.87 | 9.02 | 1.59 |
Net Cash Growth | - | - | - | 31.53% | 467.06% | 50.81% |
Net Cash Per Share | -0.51 | -24.07 | - | - | - | - |
Filing Date Shares Outstanding | 4.85 | 4.85 | 0.02 | - | - | - |
Total Common Shares Outstanding | 4.85 | 0.48 | - | - | - | - |
Working Capital | -14.97 | -9.26 | -6.06 | 9.62 | 8.39 | 1.33 |
Book Value Per Share | -3.74 | -9.81 | - | - | - | - |
Tangible Book Value | -18.17 | -4.71 | -8.05 | 10.21 | 8.45 | 1.39 |
Tangible Book Value Per Share | -3.74 | -9.81 | - | - | - | - |